Not only that, but the 36 P/E is quite expensive for CMG too. What I like so much better at a much lower P/E that's actually very profitable and growing triple digits in both revenues and EPS is REGN. Regeneron also just had great news over the weekend (on Sat.) with positive results for its drug for Atopic Dermatitis. With REGN you not only get a very profitable company that's growing in triple digits, but you get a fantastic pipeline also. So I think it's like night and day comparing CMG with Regeneron. PEG is so much lower for REGN too.